Related Experiment Video
Updated: Jan 23, 2026

Multifractal Spectrum Analysis for Assessing Pulmonary Nodule Malignancy
Published on: January 10, 2025
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
Eleni Papadokostaki1, Evangelos Liberopoulos2
1Emergency Department, General Hospital of Heraklion "Venizeleio-Pananeio," Heraklion, 71409, Greece.
Abstract:
The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes is steadily increasing. SGLT2 inhibitors are associated with weight loss, lowering of blood pressure, and low hypoglycemia risk along with beneficial cardiovascular and renoprotective effects. In view of the increasing use of SGLT2i, physicians must be aware of their adverse effects. Euglycemic diabetic ketoacidosis (euDKA) is a well-recognized adverse effect of SGLT2i. We present here a case of euglycemic diabetic ketoacidosis secondary to dapagliflozin use in a type 2 diabetic patient with colon cancer. To the best of our knowledge, this is first report of SGLT2 inhibitor-associated euDKA in a patient with underlying colon cancer.
Insights
Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer benefits for type 2 diabetes but can cause euglycemic diabetic ketoacidosis (euDKA). This case highlights euDKA from dapagliflozin in a patient with colon cancer.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors are increasingly prescribed for type 2 diabetes management.
- These agents provide benefits like weight loss, blood pressure reduction, and cardioprotective effects.
- Awareness of adverse effects, including euglycemic diabetic ketoacidosis (euDKA), is crucial for safe clinical practice.
Observation:
- A case of euDKA was observed in a patient with type 2 diabetes and colon cancer.
- The patient developed euDKA secondary to the use of dapagliflozin, an SGLT2 inhibitor.
- This presentation occurred despite maintaining relatively normal blood glucose levels.
Findings:
- This report details the first instance of SGLT2 inhibitor-associated euDKA in a patient with underlying colon cancer.
- The findings underscore the potential for euDKA as a serious adverse event associated with SGLT2 inhibitors.
- The interaction between SGLT2 inhibitors, diabetes, and malignancy warrants further investigation.
Implications:
- Physicians must maintain a high index of suspicion for euDKA in patients treated with SGLT2 inhibitors, especially those with comorbidities like cancer.
- Early recognition and management of euDKA are essential to prevent severe complications.
- This case emphasizes the need for comprehensive patient monitoring and risk assessment when prescribing SGLT2 inhibitors.
More Related Videos
Related Concept Videos
The Colonization of Land
Secondary Active Transport
Secondary Active Transport
Secondary Healthcare System
Primary and Secondary Growth in Roots and Shoots
Secondary Distribution
In residential areas, 120/240 V single-phase, three-wire service is commonly used for lighting, outlets, and large appliances. Urban areas with high-density loads...

